We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 9 februari 2018

The Lancet: [Comment] Denosumab for myeloma bone disease: ready for prime time?

[Comment] Denosumab for myeloma bone disease: ready for prime time?
Increased osteoclast activity is the hallmark of myeloma bone disease and RANKL is the most potent osteoclast activator. Bisphosphonates and monoclonal antibodies targeting RANKL (eg, denosumab) inhibit osteoclasts and are the mainstay of therapy of cancer-related bone disease. Bisphosphonates reduce skeletal-related events. Zoledronic acid, a potent bisphosphonate, improved survival compared with clodronate of patients with myeloma in a large study1 that used thalidomide-based or conventional chemotherapy.
Read more

[News] Tumour-treating fields complement glioblastoma treatment
The addition of tumour-treating fields to standard gioblastoma therapy improves progression-free survival (PFS) and does not negatively affect patients' health-related quality of life (HRQoL), according to recent findings.
Read more

[Articles] Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid for time to skeletal-related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease.
Read more

[News] Selinexor and dexamethasone in multiple myeloma
Combined treatment with selinexor and dexamethasone shows encouraging activity in patients with highly refractory multiple myeloma, according to a phase 2 trial.
Read more

[News] CAR T-cells for relapsed B-cell ALL in children and young adults
Results of a phase 2 single-cohort clinical trial show that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel provides durable remission with long-term persistence in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Read more